Wolfgang Miesbach: Factor VIII Aurora Redefines the Biology of Coagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Johnathan J. Morris et al, published in American Society of Hematology, adding:
“Haemophilia A is defined by too little factor VIII.
So what happens when FVIII works too well?
Factor VIII Aurora (FVIII-R571S) — newly characterised in Blood by Lindsey George and colleagues at CHOP — is the first naturally occurring gain-of-function FVIII variant. It was identified in a patient with recurrent thrombosis and early death (NEJM 2025), and the mechanism turns out to be strikingly simple:
A single amino acid change raises the affinity of activated FVIII for FIXa by 10–20-fold. That one property accounts for the entire phenotype:
- 6-fold higher one-stage activity, yet normal chromogenic activity — the CSA uses FIXa in excess and is blind to the difference
- ‘APC resistance’ that isn’t intrinsic: the variant is cleaved by APC normally, but tighter FIXa binding shields it
- reduced A2-domain dissociation
- 4–5-fold greater haemostatic potency and a clearly prothrombotic phenotype in mice
The gene therapy parallel is hard to miss. Just as FIX-Padua (R338L) reshaped haemophilia B gene therapy, an enhanced-potency FVIII could do the same for haemophilia A — but FVIII carries a higher VTE risk than FIX, and Aurora is a sharp reminder of how narrow the safe expression window may be.”
Title: Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity
Authors: Johnathan J. Morris, Robert J Davidson, Connor T. Watson, Lindsey A. George

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments